Roche Holding | ROG

Stock Price
345.70
Daily Change
-3.30 -0.95%
Monthly
-3.03%
Yearly
20.54%
Q4 Forecast
338.68

EPS Reference Time Actual Consensus Previous
2026-01-29 FY2025H2 8.37 10.35 2.80
2025-07-22 FY2025H1 9.23 10.8 12682000000.0000
2025-01-29 FY2024H2 2.80 8.25
2024-07-21 FY2024H1 7.80 12353000000.0000
2024-02-01 FY2023H2 8.25 8.37 10432000000.0000



Peers Price Chg Day Year Date
AbbVie 262.82 2.89 1.11% 12.36% Oct/02
Alcon AG 52.84 -0.02 -0.04% -13.86% Oct/02
Almirall 10.22 0.02 0.20% -14.41% Oct/02
Amgen 403.04 -4.23 -1.04% 35.30% Oct/02
AstraZeneca 11,870.00 -162.00 -1.35% -6.17% Oct/02
Bayer 44.94 -0.46 -1.01% 55.77% Oct/02
Biogen 219.88 -2.94 -1.32% 37.53% Oct/02
Bristol-Myers Squibb 61.15 -0.31 -0.50% 34.54% Oct/02
Fresenius Medical Care 39.55 -0.13 -0.33% -13.21% Oct/02
Fresenius 43.64 -0.17 -0.38% -7.47% Oct/02

Indexes Price Day Year Date
CH20 13661 38.07 0.28% 9.22% Oct/02
EU600 631 0 0% 10.68% Oct/02

Roche Holding traded at 345.70 this Friday October 2nd, decreasing 3.30 or 0.95 percent since the previous trading session. Looking back, over the last four weeks, Roche Holding lost 3.03 percent. Over the last 12 months, its price rose by 20.54 percent. Looking ahead, we forecast Roche Holding to be priced at 338.68 by the end of this quarter and at 318.47 in one year, according to Trading Economics global macro models projections and analysts expectations.

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.



News Stream
Roche Holding Stock Price Hits Near 4-year High
Roche Holding shares increased to 362.40 CHF, the highest since May 2022. Over the past 4 weeks, Roche Holding gained 4.21%, and in the last 12 months, it increased 22.55%.
2026-02-17
Roche Holding Stock Price Hits 3-year High
Roche Holding shares increased to 349.75 CHF, the highest since May 2022. Over the past 4 weeks, Roche Holding gained 6.68%, and in the last 12 months, it increased 25.17%.
2026-01-26
Roche Holding Stock Price Hits 3-year High
Roche Holding shares increased to 331.25 CHF, the highest since November 2022. Over the past 4 weeks, Roche Holding gained 4.19%, and in the last 12 months, it increased 25.19%.
2026-01-06